NCT00210379View on ClinicalTrials.gov

Phase II Study of Combined Modality Treatment in Primary Testicular Non-Hodgkin's Lymphoma

PHASE2CompletedINTERVENTIONAL
Enrollment

64

Participants

Timeline

Start Date

November 30, 2000

Primary Completion Date

November 30, 2004

Study Completion Date

March 31, 2007

Conditions
Lymphoma, B Cell
Interventions
DRUG

rituximab

DRUG

CHOP

DRUG

intrathecal methotrexate

PROCEDURE

radiotherapy

Trial Locations (1)

6500

Oncology Institute of Southern Switzerland (IOSI), Bellinzona

All Listed Sponsors
lead

International Extranodal Lymphoma Study Group (IELSG)

OTHER

NCT00210379 - Phase II Study of Combined Modality Treatment in Primary Testicular Non-Hodgkin's Lymphoma | Biotech Hunter | Biotech Hunter